Journal
NEUROREPORT
Volume 11, Issue 12, Pages 2675-2679Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00001756-200008210-00014
Keywords
blood flow; cerebral ischemia; neuroprotection; TTC
Categories
Funding
- NINDS NIH HHS [NS 35,205] Funding Source: Medline
Ask authors/readers for more resources
Inhibitors of cell-swelling-activated anion channels, including the antiestrogenic compound tamoxifen (TAM), have been shown to attenuate the increase in excitatory amino acids (EAA) during ischemia. Since TAM enters the CNS we tested whether it provides protection from damage due to reversible middle cerebral artery occlusion (rMCAo) in rats. TAM (5 mg/kg, i.v.) infused 25 min before ischemia, potently reduced the total volume of the infarct from 328 +/- 34 mm(3) to 41 +/- 21 mm(3), a reduction of 87%, as measured by TTC staining. It was equally effective when infused starting at 1 h after reperfusion, i.e. 3 h after initiation of rMCAo. Protection of neurons was also found histologically. TAM had no effect on CBF as measured by hydrogen clearance. This appears to be the first report of a marked neuroprotective effect of TAM. Further studies are needed to determine whether its effects are due to inhibition of EAA release and/or other potential neuroprotective sites of action. (C) 2000 Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available